APA (7th ed.) Citation

AM, Z., K, P., T, S., T, W., & RS, E. (2024). Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms. Therapeutic advances in hematology, 15, 20406207241257313. https://doi.org/10.1177/20406207241257313

Chicago Style (17th ed.) Citation

AM, Zeidan, Perepezko K, Salimi T, Washington T, and Epstein RS. "Patients' Perspectives on Oral Decitabine/cedazuridine for the Treatment of Myelodysplastic Syndromes/neoplasms." Therapeutic Advances in Hematology 15 (2024): 20406207241257313. https://doi.org/10.1177/20406207241257313.

MLA (9th ed.) Citation

AM, Zeidan, et al. "Patients' Perspectives on Oral Decitabine/cedazuridine for the Treatment of Myelodysplastic Syndromes/neoplasms." Therapeutic Advances in Hematology, vol. 15, 2024, p. 20406207241257313, https://doi.org/10.1177/20406207241257313.